RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence

Papillary thyroid cancer (PTC) is the most common epithelial thyroid tumor, accounting for more than 80% of all thyroid cancers. Although PTC shows an indolent character and excellent prognosis, patients with aggressive characteristics are more likely to have a disease recurrence and die in the end. The aim of this study was to analyze BRAF^V600E mutation and methylation levels of CpG sites in the promoters of CDH1, DAPK, RARβ and RUNX3 genes in a cohort of PTCs, and investigate their association with tumor recurrence. In this study, we used pyrosequencing method to individually quantified methylation levels at multiple CpG sites within each gene promoter, and detect BRAF^V600E mutation in 120 PTCs and 23 goiter tissues as normal control. Moreover, appropriate cut-off values for each CpG site were set up to predict disease recurrence. Our data showed that overall average methylation levels of CDH1 and RUNX3 genes were significantly higher in PTCs than that in control subjects. Conversely, overall average methylation levels of DAPK promoter were significantly lower in PTCs than that in control subjects. Moreover, BRAF^V600E mutation and overall average methylation levels of all these genes were not significant difference between recurrent and non-recurrent cases. However, we found that hypermethylation of RUNX3 at CpG sites -1397, -1406, -1415 and -1417 significantly increased the risk of of disease recurrence by using appropriate site-specific cut-off values. Collectively, our findings suggest RUNX3 site-specific hypermethylation may offer value in predicting or monitoring postoperative recurrence of PTC patients.     

MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma

Escalating evidence suggests that microRNA-101 (miR-101) is implicated in the development and progression of various cancers, including papillary thyroid carcinoma (PTC). However, the biological function and molecular mechanisms of miR-101 in PTC are still unclear. In this study, we demonstrated that miR-101 expression was significantly decreased in PTC tissues and cell lines. Clinically, a low level of miR-101 was positively associated with advanced histological stages and lymph node and distant metastases. The expression of CXCL12 was negatively correlated with miR-101 level in PTC. CXCL12 was validated as a direct target of miR-101 in PTC cells. Functional experiments proved that miR-101 markedly reduced the proliferation, apoptosis escape, migration, and invasion of PTC cells. Moreover, CXCL12 restoration rescued the suppressive effects of miR-101 on PTC cells by activating Akt- and EMT-associated signaling pathways. Overall, miR-101 exerts oncostatic effects on PTC by downregulating CXCL12 and repressing its downstream Akt and Snail signaling pathways, suggesting that miR-101/CXCL12/Akt or Snail axis may serve as a potential therapeutic target for PTC.     

Posterior tibial slope measurement on lateral knee radiographs as a risk factor of anterior cruciate ligament injury: A cross-sectional study

Introduction

The posterior tibial slope (PTS) is believed to be a risk factor for anterior cruciate ligament (ACL) injury. The aim of this study was to reveal the differences in terms of PTS measurements on lateral knee radiographs between ruptured and non-injured cases as well as between males and females in regard to ACL alignment.

Research trends for papillary thyroid carcinoma from 2010 to 2019: A systematic review and bibliometrics analysis

Background:Thyroid carcinoma comprises the fastest rising incidence of carcinomas over the past decade. Papillary thyroid carcinoma (PTC) is the most predominant type of thyroid carcinoma. This study aimed to assess the research trends in the field of PTC.Methods:Publications from January 2010 to December 2019 were retrieved from the Web of Science Core Collection database using Thompson Reuters. Searching strategies were determined according to Medical Subject Heading terms. Different kinds of bibliometrics software, such as HistCite and VOSviewer, and online bibliometrics analysis platforms were utilized to evaluate and visualize the results.Results:A total of 8102 publications across 93 countries were identified, with the annual number of publications showing an increasing trend. The United States, China, and South Korea showed their dominant position in PTC publication outputs, H-index, total citations, and international collaborations. Thyroid was the most productive journal. Akira Miyauchi published the most articles, and the most productive institution was Yonsei University. The hotspots keywords proliferation, invasion and metastasis, diagnoses and prognoses, therapeutic resistance, recurrence, and microcarcinomas appeared earlier and were sustained over the last 3 years.Conclusions:This bibliometric study provides a comprehensive analysis delineating the scientific productivity, collaboration, and research hotspots within the PTC field, which will be very helpful when focusing on the direction of research over the next few years.     

ER、PR、Her-2/neu在甲状腺乳头状癌中的表达及意义

目的:探讨雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(Her-2/neu)在甲状腺乳头状癌中的表达及意义。方法:收集甲状腺乳头状癌共43例,结节性甲状腺肿8例,癌旁正常甲状腺组织4例。用免疫组化SP法检测ER、PR、Her-2/neu在甲状腺组织中的表达,并分析这些蛋白表达与甲状腺肿瘤生物学特征的关系。结果:5例男性标本ER、PR、Her-2/neu阳性表达率分别为40%(2/5)、40%(2/5)、60%(3/5),39例女性阳性表达率分别为56.41%(22/39)、48.71%(19/39)、61.53%(24/39)。年龄>45岁的标本19例,阳性表达率分别为57.89%(11/19)、57.89%(11/19)、68.42%(11/19),年龄<45岁标本24例,阳性表达率分别为54.16%(13/24)、41.66%(10/24)、58.33%(14/24)。有淋巴结转移16例标本,阳性表达率分别为68.75%(11/16)、75%(12/16)、81.25%(13/16),无淋巴结转移27例标本,阳性表达率分别为48.14%(13/27)、33.33%(9/27)、1.85%(14/27)。结论:ER、PR、Her-2/neu在甲状腺乳头状癌中有较高的阳性表达,三者的阳性表达与年龄、性别无关,与是否发生淋巴结转移有关,这为甲状腺乳头状癌的诊断、治疗和判断预后提供了一条新的途径。     

BRAF基因V600E突变与Ⅰ～Ⅱ期乳头状甲状腺癌临床病理特征及预后的相关性分析

目的 探讨Ⅰ～Ⅱ期乳头状甲状腺癌（PTC）患者肿瘤组织中BRAF基因V600E突变情况,并分析其与临床病理特征及预后的关系。方法 采用RT-PCR法检测374例Ⅰ～Ⅱ期PTC患者组织样本中BRAF基因V600E突变,并分析其与临床病理特征及预后的关系。 结果 374例PTC患者标本中BRAF基因V600E的突变率为40.37％（151／374）。BRAF基因V600E突变与包膜侵犯、多灶、多次131I治疗相关（P＜0.05）。374例 PTC患者中31例复发,复发患者中有BRAF基因V600E突变的22例。31例复发病例中,BRAF基因V600E突变患者的中位生存期为5.3年（95％CI：3.9～6.7年）,未突变患者为7.0年（95％CI：5.1～8.9年）,差异无统计学意义（P＞0.05）。Logistic多因素回归分析显示,BRAF基因V600E突变及包膜侵犯是Ⅰ～Ⅱ期PTC患者复发的独立危险因素（P＜0.05）。 结论 BRAF基因V600E突变可能是Ⅰ～Ⅱ期PTC患者预后的一项重要预测指标。     

PCNA、VEGF、ER在甲状腺乳头状癌中的表达及临床意义

目的探讨PCNA、VEGF、ER在甲状腺乳头状癌等组织中的表达及临床意义。方法对30例甲状腺乳头状癌和30例癌旁正常甲状腺组织,用免疫组化S-P法,检测PCNA、VEGF、ER表达。结果PCNA、VEGF、ER在甲状腺乳头状癌中的表达率显著高于癌旁正常甲状腺组织（P〈0.01）。三者在甲状腺乳头状癌中表达率具有相关性。结论PCNA、VEGF、ER表达可作为甲状腺癌的协助诊断指标,对临床治疗和预后判断具有重要的指导意义。